Genetron Holdings Dirección

Dirección controles de criterios 2/4

El CEO de Genetron Holdings' es Sizhen Wang, nombrado en May 2015, tiene una permanencia de 8.92 años. posee directamente un 5.33% de las acciones de la empresa, con un valor de $6.79M. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 3.8 años, respectivamente.

Información clave

Sizhen Wang

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	8.9yrs
Participación del CEO	5.3%
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 17

Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

Mar 27

Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?

Feb 25

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

Jan 06

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China

Nov 27

Genetron (GTH) Investor Presentation - Slideshow

Nov 18

Genetron Holdings reports Q3 results

Nov 09

CEO

Sizhen Wang (45 yo)

8.9yrs

Permanencia

Mr. Sizhen Wang has been Chairman at Genetron Holdings Limited since June 2021. He is the Co-Founder of Genetron Holdings Limited. He has been Director at Genetron Holdings Limited since April 2018 and has...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sizhen Wang	Co-Founder	8.9yrs	sin datos	5.33% CN¥ 6.8m
Wei-Wu He	Co-Founder & Chairman Emeritus	no data	sin datos	4.3% CN¥ 5.5m
Hai Yan	Co-Founder	no data	sin datos	6.99% CN¥ 8.9m
Ce Xu	Chief Financial Officer	6.1yrs	sin datos	sin datos
Victoria Lei	Chief Operating Officer	1.8yrs	sin datos	sin datos
Yuchen Jiao	Chief Technology Officer	6.7yrs	sin datos	0.78% CN¥ 989.3k
Yong Liang	Chief Human Resources Officer	2.3yrs	sin datos	sin datos
Yun-Fu Hu	Chief Medical Officer	4yrs	sin datos	sin datos
Lily Liu	Chief Commercial Officer	1.8yrs	sin datos	sin datos

4.0yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GTH se considera experimentado (4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sizhen Wang	Co-Founder	6yrs	sin datos	5.33% CN¥ 6.8m
Wei-Wu He	Co-Founder & Chairman Emeritus	2.8yrs	sin datos	4.3% CN¥ 5.5m
Hai Yan	Co-Founder	no data	sin datos	6.99% CN¥ 8.9m
Dian Kang	Independent Director	3.8yrs	sin datos	sin datos
Webster Cavenee	Independent Director	3.8yrs	sin datos	sin datos
Wing Kee Lau	Independent Director	3.8yrs	sin datos	sin datos
Shan Fu	Non Executive Director	2.8yrs	sin datos	sin datos
Xia Wu	Non-Executive Director	6.6yrs	sin datos	sin datos
Chao Tang	Non Executive Director	2.8yrs	sin datos	sin datos

3.8yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de GTH se considera experimentada (3.8 años de antigüedad promedio).

Genetron Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Less than half of directors are independent

Chief Technology Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Recent updates

Genetron Holdings Files Form 15

Genetron Holdings Requests Nasdaq to File Form 25 with the Securities and Exchange Commission for Delisting of the ADSs on Nasdaq and the Deregistration of its Registered Securities

New minor risk - Shareholder dilution

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genetron Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

Less than half of directors are independent

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Minimum Bid Price

Second quarter 2022 earnings released: CN¥2.54 loss per share (vs CN¥1.00 loss in 2Q 2021)

Genetron Holdings GAAP EPS of -$0.08, revenue of $20.56M

Sizhen Wang made a non binding proposal to acquire the remaining 49.2% stake in Genetron Holdings Limited (NasdaqGM:GTH) from Genetron Health (Hong Kong) Company Limited and others for $60 million.

China's Genetron gets acquisition offer from co-founder/CEO

Genetron Holdings Limited to Report Q1, 2022 Results on Jun 02, 2022

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to US$6.51

Consensus EPS estimates fall by 24%

Less than half of directors are independent

Consensus EPS estimates fall by 24%

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Genetron Holdings Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2021

Genetron Holdings Limited Reiterates Full Year 2021 Revenue Guidance

Chief Technology Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Are Investors Undervaluing Genetron Holdings Limited (NASDAQ:GTH) By 27%?

Chief Financial Officer notifies of intention to sell stock

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$18.92

Genetron Holdings Limited Provides Revenue Guidance for the Full Year 2021

Price target decreased to US$22.63

Co-Founder notifies of intention to sell stock

Second quarter 2021 earnings released

Genetron Holdings Limited Maintains Revenue Guidance for the Year 2021

Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price

Genetron Health Limited Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

Chief Operating Officer Ying Hong has left the company

Non-Executive Director Weidong Liu has left the company

Genetron Holdings Limited Reiterates 2021 Financial Guidance

First quarter 2021 earnings released: CN¥1.23 loss per share (vs CN¥4.62 loss in 1Q 2020)

Full year 2020 earnings released: CN¥50.92 loss per share (vs CN¥27.06 loss in FY 2019)

Consensus forecasts updated

Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

Genetron Holdings Limited Provides Revenue Guidance for Year 2021

Full year 2020 earnings released: CN¥50.92 loss per share (vs CN¥27.06 loss in FY 2019)

Genetron Holdings Limited to Report Q4, 2020 Results on Mar 25, 2021

Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?

New 90-day high: US$28.04

New 90-day high: US$23.47

Genetron Health Announces Exclusive Strategic Partnership with Chia Tai Tianqing Pharmaceutical Group Co., Ltd

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

New 90-day high: US$14.00

Genetron Holdings Limited Provides an Update for Hccscreentm, Its Blood-Based Early Screening Test for Hepatocellular Carcinoma (“Hcc”), in China

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China

New 90-day high: US$13.27

Genetron (GTH) Investor Presentation - Slideshow

Analysts increase EPS estimates to -CN¥10.14

Genetron Holdings reports Q3 results

Genetron Holdings Limited to Report Q3, 2020 Results on Nov 09, 2020

Genetron Holdings Limited Receives U.S. FDA Breakthrough Device Designation for its Blood-based NGS Test for Early Detection of Hepatocellular Carcinoma

Genetron Holdings Limited and Cstone Pharmaceuticals Announce Launch of Clinical Trial in China for Companion Diagnostic Test in Development for Avapritinib

New 90-day low: US$10.80

Genetron Health and Dmed Announce Partnership Agreement

First half earnings released

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad